Jump to content

Vandortuzumab vedotin

From Wikipedia, the free encyclopedia
Vandortuzumab vedotin
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetSTEAP1
Clinical data
Other namesRG7450
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6608H10168N1756O2076S44
Molar mass148838.89 g·mol−1

Vandortuzumab vedotin (INN; development code RG7450) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]

This drug was developed by Genentech/Roche. Development was discontinued in 2017.[3]

References

[edit]
  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vandortuzumab Vedotin, American Medical Association.
  2. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).
  3. ^ "Vandortuzumab vedotin". AdisInsight. Springer Nature Switzerland AG.